Replies to post #425876 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Also, the MOA.

... have "concluded" that blarcamesine works;

Two things about this conclusion.

First is the abundance of clinical evidence of safety and efficacy, in both murines (lab test rodents) and humans.

But the other big question is how blarcamesine can cause its good outcomes. It's the MOA, mechanism of action; biochemically how the molecule causes good cellular things to happen.

Blarcamesine contrasts definitively with the newly-approved anti-amyloid drugs. Those drugs induce the immune system to chemically attack and remove the waste proteins thought to be the cause of Alzheimer's symptoms. Good idea, but in practice not so workable. Lots of undesired side effects with these drugs. And, their removal of amyloid deposits is weak and incomplete; on the now questionable presumption that forcing the immune system to chemically attack the amyloids will actually bring strong, enduring symptomatic relief. Very, very weak evidence for this.

Blarcamesine works entirely differently, by attaching to and activating the sigma-1 receptor protein. By doing this, the activated sigma-1 protein is able to make a diversity of "downstream" cellular processes work as they should; such as causing proteins to be properly folded, which then allows those proteins, enzymes, to catalytically make proper chemical reactions in the cell.

There is a diversity of other chemical processes that properly functioning, activated sigma-1 receptors modulate. Simply, if the sigma-1 receptor works as it should, so does the cell. The blarcamesine MOA is far better than inducing the immune system to attack amyloid proteins.

Blarcamesine's superiority is revealed by both the existing clinical evidence and also by its unique mechanism of action.

[Mkc12five]

Rest assured that the amount of greed and manipulation that has occurred in driving this stock down will eventually swing the other way. When that happens it will be a thing to behold.